Proof from partnerships

Multiple partnerships for an adeno-associated virus platform generated the data that helped RegenxBio Inc. attract new investors to a $30 million series C round that will allow the company to develop its downstream capabilities and advance two in-house gene therapies into the clinic.

Venrock and Brookside Capital led last week's round and were joined by fellow new investor Deerfield Management, an undisclosed new investor and existing investors FoxKiser and Fidelity Biosciences...